Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (NASDAQ: BCRX) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024 results, they traded its shares down by an even 10% on the day. That fall was far steeper than the 0.5% slip of the benchmark S&P 500 (SNPINDEX: ^GSPC).
For the quarter, BioCryst managed to increase its revenue by 41% to $131.5 million. The company also narrowed its generally accepted accounting principles (GAAP) net loss; this came in at $26.8 million ($0.13 per share) against the $61.7 million deficit it posted in the same quarter the previous year.
The biotech beat the consensus analyst estimate for revenue, which was slightly over $127 million. However, it missed quite widely for net loss, as those pundits were collectively anticipating only a $0.07 per share shortfall.
Source Fool.com
